“Gut Microbiota Metabolites As A New Therapeutic Target In Patients With Coronary Artery Disease And Atrial Fibrillation” (2023) Journal of Pharmaceutical Negative Results, pp. 1221–1227. doi:10.47750/pnr.2023.14.02.157.